
https://www.science.org/content/blog-post/wait-we-didn-t-tell-you-about-endpoint
# Wait, We Didn't Tell You About That Endpoint? (November 2014)

## 1. SUMMARY

The Science article discusses concerns about endpoint switching in clinical trials, focusing on NeoStem, a small stem-cell company that announced results for a cardiac stem cell therapy trial. The author highlights that a bearish trader following the company discovered that the primary endpoints had been significantly changed in the ClinicalTrials.gov record after the fact. 

The original measurements of myocardial perfusion had been de-emphasized, while measurements of major adverse cardiac events had been added. The piece suggests that the company likely saw no meaningful differences in the original endpoints, while seeing "encouraging" but still not statistically significant numbers in the newly added endpoints. The article questions the ethical boundaries of such changes and notes that despite the company's "positive data" press release, NeoStem's stock suffered substantial losses, though the author wonders if the losses would have been greater if more investors had read the details more carefully.

## 2. HISTORY

NeoStem went through significant corporate changes after this 2014 article. In 2015, the company acquired Caladrius Biosciences and subsequently changed its name to Caladrius Biosciences, Inc. The cardiac therapy mentioned in the article was likely the company's CD34+ cell therapy program, which showed mixed results.

Looking at the broader trajectory:

- **Corporate Evolution**: NeoStem transitioned from a broad-based cell therapy company into Caladrius Biosciences with a more focused pipeline on T-cell therapies and regenerative medicine approaches.

- **Clinical Outcomes**: The company's vascular repair programs, including those for cardiac applications, faced ongoing challenges. Most cellular therapies for heart disease have generally struggled to demonstrate consistent clinical benefits over the past decade, with many trials showing marginal or inconsistent improvements.

- **Market Performance**: NeoStem/Caladrius remained a small-cap biotech company and continued to face financial pressures typical of pre-revenue biotech companies. The biotech sector as a whole saw significant volatility, particularly in 2015-2016 and during the pandemic years.

- **Regulatory Environment**: The concerns raised about endpoint switching contributed to ongoing discussions about clinical trial transparency and data integrity, though no major regulatory actions specific to this case appear to have resulted.

## 3. PREDICTIONS

The 2014 article did not make specific long-term predictions about the field or company, focusing instead on the immediate concerns about clinical trial transparency and endpoint changes. However, it did raise an implicit question about whether more investors reading the details would have led to even greater stock losses for NeoStem.

- **Market Reaction**: The implicit expectation was that full understanding of the endpoint switching would lead to additional negative market reaction. ✓ **Confirmed**: NeoStem's transition to Caladrius and ongoing struggles suggest investors remained skeptical, though the company persisted through various corporate restructurings.

- **Broader Industry Impact**: The article implied that such practices could undermine confidence in clinical trial reporting. ✓ **Partially confirmed**: While this specific case didn't cause major regulatory changes, concerns about clinical trial transparency and endpoint selection have remained ongoing issues in biotech and drug development, with continued calls for improved standards.

## 4. INTEREST

**Score: 4**

While interesting as case study of questionable clinical trial practices, this story did not have major long-term impact and involved a relatively minor company.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20141119-wait-we-didn-t-tell-you-about-endpoint.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_